- Home
- RNAZ vs EPIX Comparison
RNAZ vs EPIX Comparison
Compare RNAZ & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- EPIX
- Stock Information
- Founded
- RNAZ 2016
- EPIX 2009
- Country
- RNAZ United States
- EPIX Canada
- Employees
- RNAZ N/A
- EPIX N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- EPIX Health Care
- Exchange
- RNAZ Nasdaq
- EPIX Nasdaq
- Market Cap
- RNAZ 8.7M
- EPIX 9.0M
- IPO Year
- RNAZ 2021
- EPIX N/A
- Fundamental
- Price
- RNAZ $15.00
- EPIX $0.20
- Analyst Decision
- RNAZ Strong Buy
- EPIX Hold
- Analyst Count
- RNAZ 1
- EPIX 3
- Target Price
- RNAZ $280.00
- EPIX $2.00
- AVG Volume (30 Days)
- RNAZ 13.8K
- EPIX 3.2M
- Earning Date
- RNAZ 11-13-2025
- EPIX 08-13-2025
- Dividend Yield
- RNAZ N/A
- EPIX N/A
- EPS Growth
- RNAZ N/A
- EPIX N/A
- EPS
- RNAZ N/A
- EPIX N/A
- Revenue
- RNAZ N/A
- EPIX N/A
- Revenue This Year
- RNAZ N/A
- EPIX N/A
- Revenue Next Year
- RNAZ N/A
- EPIX N/A
- P/E Ratio
- RNAZ N/A
- EPIX N/A
- Revenue Growth
- RNAZ N/A
- EPIX N/A
- 52 Week Low
- RNAZ $6.15
- EPIX $0.18
- 52 Week High
- RNAZ $739.20
- EPIX $6.48
- Technical
- Relative Strength Index (RSI)
- RNAZ 84.37
- EPIX 11.88
- Support Level
- RNAZ $10.32
- EPIX $0.20
- Resistance Level
- RNAZ $12.28
- EPIX $0.22
- Average True Range (ATR)
- RNAZ 0.87
- EPIX 0.01
- MACD
- RNAZ 0.57
- EPIX 0.06
- Stochastic Oscillator
- RNAZ 91.34
- EPIX 36.04
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.